AltaRex Corp.

AltaRex Corp. is an antibody-based immunotherapy company focused on the research, development and commercialization of unique therapeutics for the treatment of cancers. The Company s most advanced product, OvaRex, MAb, is in two potentially pivotal Phase IIb trials for the treatment of ovarian cancer. The U.S. Food and Drug Administration has granted OvaRex, MAb both Orphan Drug status and a Fast Track designation, making possible a 2002 commercialization. The Company s products are based on its unique proprietary platform technology, Antibody-based Immunotherapy (AITŪ). The Company has evidence to suggest AITŪ enhances the ability of the human immune system to produce a highly effective anti-tumor response through multiple mechanisms. AltaRex currently has four AITŪ based products in various stages of development that have the potential to effectively treat seven of the top ten most lethal cancers.

Activity:

Product / Technology type(s) covered:

- Pharmaceuticals / Therapeutics
- Technology

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: